1,2-双(3,5-二氟苯基)乙烷-1,2-二酮 | 223707-22-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 中文名称: 1,2-双(3,5-二氟苯基)乙烷-1,2-二酮
• 英文名称: 1,2-bis(3,5-difluorophenyl)ethane-1,2-dione
• 英文别名: 1,2-di(3,5-difluorophenyl)ethane-1,2-dione；3,3',5,5'-tetrafluorobenzil
• CAS: 223707-22-0
• 化学式: C₁₄H₆F₄O₂
• 分子量: 282.194
• InChiKey: ZDXXQKFXZDPNLI-UHFFFAOYSA-N

物化性质

• 熔点：
  135-137 °C
• 沸点：
  376.5±42.0 °C(Predicted)
• 密度：
  1.430±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  34.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,2-双(3,5-二氟苯基)乙烷-1,2-二酮 、 二苄基甲酮 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 0.75h， 以88.2%的产率得到2,5-diphenyl-3,4-di(3,5-difluorophenyl)cyclopentadienone
  参考文献：
  名称：

  硝基和氟取代的四苯基-苯基接枝的聚硅氧烷作为毛细管气相色谱的固定相

  摘要：

  这项工作报告2,5-二（4-硝基苯基）-3,4-二（3,5-二氟苯基）苯基接枝的聚硅氧烷（NDPP;包含12.4％2,5-二（4-硝基苯基）-3 ，4-二（3,5-二氟苯基）苯基）用于气相色谱（GC）分离。热重分析表明，在385°C时，NDPP聚合物的重量损失了2％。NDPP色谱柱上的醇色谱分析表明，NDPP固定相具有良好的热稳定性。在120°C下通过萘测定，柱效为10 m柱每m 3460板/ m和30 m柱每m 3700板。固定相具有中等极性，这一点已通过McReynolds常数确认。亚伯拉罕系统常数表明，NDPP与溶质之间的主要相互作用是偶极诱导的偶极相互作用和氢键力。根据π–π叠加，偶极子-偶极子，由于偶极诱导的偶极和氢键相互作用，NDPP固定相对异构体具有有利的分辨能力。NDPP固定相对多组分混合物，取代的苯，多环芳烃及其衍生物和醚也显示出优异的选择性。

  DOI：

  10.1039/c9nj01246j
• 作为产物：
  描述：

  3,5-二氟苯甲醛 在 sodium hydroxide 、 硝酸铵 、 copper (I) acetate 、 盐酸硫胺 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 生成 1,2-双(3,5-二氟苯基)乙烷-1,2-二酮
  参考文献：
  名称：

  Identification and Characterization of Novel Benzil (Diphenylethane-1,2-dione) Analogues as Inhibitors of Mammalian Carboxylesterases

  摘要：

  Carboxylesterases (CE) are ubiquitous enzymes responsible for the metabolism of xenobiotics. Because the structural and amino acid homology among esterases of different classes, the identification of selective inhibitors of these proteins has proved problematic. Using Telik's target-related affinity profiling (TRAP) technology, we have identified a class of compounds based on benzil (1,2-diphenylethane-1,2-dione) that are potent CE inhibitors, with K-i values in the low nanomolar range. Benzil and 30 analogues demonstrated selective inhibition of CEs, with no inhibitory activity toward human acetylcholinesterase or butyrylcholinesterase. Analysis of structurally related compounds indicated that the ethane- 1,2-dione moiety was essential for enzyme inhibition and that potency was dependent on the presence of, and substitution within, the benzene ring. 3D-QSAR analyses of these benzil analogues for three different mammalian CEs demonstrated excellent correlations of observed versus predicted K-i (r(2) > 0.91), with cross-validation coefficients (q(2)) of 0.9. Overall, these results suggest that selective inhibitors of CEs with potential for use in clinical applications can be designed.

  DOI：

  10.1021/jm049011j

文献信息

• Synthesis of electron-poor hexa-peri-hexabenzocoronenes
  作者：David J. Jones、Balaji Purushothaman、Shaomin Ji、Andrew B. Holmes、Wallace W. H. Wong

  DOI：10.1039/c2cc33892k

  日期：——

  The oxidative cyclodehydrogenation of electron-poor arenes was achieved using DDQ-CF(3)SO(3)H resulting in hexa-peri-hexabenzocoronenes with electron withdrawing Br, F and CF(3) groups. This method will lead to their expansion into a new class of electron transport materials.

  使用DDQ-CF（3）SO（3）H可以实现贫电子芳烃的氧化环脱氢反应，生成带有吸电子Br，F和CF（3）基团的六-周边-六苯甲酮。这种方法将导致它们扩展为一类新的电子传输材料。
• Light Emitting Element and Light Emitting Device
  申请人：Ohsawa Nobuharu

  公开号：US20070241667A1

  公开（公告）日：2007-10-18

  It is an object of the present invention to obtain an organometallic complex that is capable of converting an excited triplet state into luminescence, a light-emitting element that can be driven for a long time, is high in luminous efficiency, and has a favorable long lifetime, and a light-emitting device using the light-emitting element. The present invention provides a light-emitting element that has a pair of electrodes (an anode and a cathode) and a light-emitting layer between a pair of electrodes, where the light-emitting layer includes an organometallic complex represented by the following general formula (5) and one of a compound that has a larger energy gap than the organometallic complex and a compound that has a larger ionization potential and a smaller electron affinity than the organometallic complex, and provides a light-emitting device using the light-emitting device.

  本发明的目的是获得一种有机金属配合物，能够将激发的三重态状态转化为发光，具有长时间驱动、高发光效率和良好长寿命的发光元件，以及使用该发光元件的发光装置。本发明提供了一种发光元件，其具有一对电极（阳极和阴极）和位于一对电极之间的发光层，其中发光层包括由下列通式（5）表示的有机金属配合物和具有比有机金属配合物更大能隙的化合物或具有比有机金属配合物更大离化势和更小电子亲和力的化合物之一，并提供使用该发光元件的发光装置。
• Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them
  申请人：——

  公开号：US20020119991A1

  公开（公告）日：2002-08-29

  A compound of formula 1 1 wherein: A is a group selected from 2 X − is an anion with a single negative charge; R 1 and R 2 are each independently a C 1 -C 4 -alkyl optionally substituted with hydroxy or halogen; and R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, hydroxy, CF 3 , CN, NO 2 , or halogen, with the proviso that at least one of the groups R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.

  化合物的化学式为11，其中：A是从2X−中选择的基团，2X−是带有单负电荷的阴离子；R1和R2各自独立地是C1-C4烷基，可选地被羟基或卤素取代；R3、R4、R5、R6、R7和R8各自独立地是氢、C1-C4烷基、C1-C4烷氧基、羟基、CF3、CN、NO2或卤素，但至少有一个基团R3、R4、R5、R6、R7和R8不是氢。本发明还涉及制备这些化合物的方法、含有这些化合物的药物组合物以及它们作为药物组合物的用途。
• Anticholinergics, processes for preparing them and pharmaceutical composition containing them
  申请人：Meissner Helmut

  公开号：US20050054664A1

  公开（公告）日：2005-03-10

  A compound of formula 1 wherein: A is a group selected from X − is an anion with a single negative charge; R 1 and R 2 are each independently a C 1 -C 4 -alkyl optionally substituted with hydroxy or halogen; and R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are each independently hydrogen, C 1 -C 4 -alkyl, C 1 -C 4 -alkyloxy, hydroxy, CF 3 , CN, NO 2 , or halogen, with the proviso that at least one of the groups R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 is not hydrogen, processes for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as pharmaceutical compositions.

  化合物公式1，其中：A是从X-选择的基团，X-是带有单负电荷的阴离子；R1和R2分别独立地是C1-C4烷基，可选地取代羟基或卤素；而R3、R4、R5、R6、R7和R8分别独立地是氢、C1-C4烷基、C1-C4烷氧基、羟基、CF3、CN、NO2或卤素，但其中至少有一个基团R3、R4、R5、R6、R7或R8不是氢。制备这些化合物的方法，包含这些化合物的制药组合物以及它们作为制药组合物的用途。
• Organometallic Complex, And Light-Emitting Element And Light-Emitting Device Using The Same
  申请人：Inoue Hideko

  公开号：US20080113216A1

  公开（公告）日：2008-05-15

  It is an object of the present invention to provide a substance capable of emitting phosphorescence. In addition, it is an object of the present invention to provide a light-emitting element that is excellent in chromaticity. One aspect of the present invention is an organometallic complex having a structure represented by a general formula ( 1 ). In the general formula ( 1 ), R 1 to R 4 are each any one of hydrogen, a halogen element, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a cyano group, and a heterocyclic group. In addition, R 5 to R 13 are each any one of hydrogen, an acyl group, an alkyl group, an alkoxyl group, an aryl group, a heterocyclic group, and an electron-withdrawing group. An organometallic complex having such a structure can emit phosphorescence with higher emission intensity.

  本发明的目的是提供一种能够发出磷光的物质。此外，本发明的目的是提供一种色度优异的发光元件。本发明的一个方面是具有由通式（1）表示的结构的有机金属配合物。在通式（1）中，R1至R4分别是氢、卤素元素、酰基、烷基、烷氧基、芳基、氰基和杂环基中的任意一种。此外，R5到R13分别是氢、酰基、烷基、烷氧基、芳基、杂环基和电子吸引基中的任意一种。具有这种结构的有机金属配合物可以发出更高强度的磷光。